(Juventas Therapeutics, Inc. is formerly known as AcelleRX Therapeutics, Inc.)
2011
April 26, 2011 - Juventas Therapeutics Completes Successful Phase I Clinical Trial for JVS-100 in Treatment of Patients with Heart Failure
January 3, 2011 - Juventas Therapeutics Initiating Phase II Clinical Trial of JVS-100 for Treatment of Critical Limb Ischemia
2010
April 5, 2010 - Juventas Therapeutics Enrolling Phase I Clinical Trial of JVS-100 for Patients with Heart Failure2009
2008
October 9, 2008 - AcelleRX receives $6.9 million investment
2007
July 30, 2007 - AcelleRX secures $1.5 million in financing